Intracranial Response Pattern, Tolerability and Biomarkers Associated with Brain Metastases in Non-small Cell Lung Cancer Treated by Tislelizumab Plus Chemotherapy

Overview

Journal Transl Lung Cancer Res

Date 2024 Mar 18

PMID 38496686

Authors

Shen Zhao

Wei Jiang

Nong Yang

Li Liu

Yan Yu

Qiming Wang

Yuanyuan Zhao

Yunpeng Yang

Shuxiang Ma

Qitao Yu

Li Zhang

Yan Huang

Affiliations

Soon will be listed here.

Abstract

Background: Programmed cell death protein-1/programmed cell death protein-ligand 1 (PD-1/PD-L1) inhibitor and chemotherapy are the standard treatment for advanced non-small cell lung cancer (NSCLC) without sensitizing mutations. However, patients with untreated, symptomatic or recently-irradiated brain metastases (BMs) are mostly excluded from immunochemotherapy trials. This study aims to evaluate the intracranial response pattern, tolerability and biomarkers of tislelizumab plus chemotherapy in NSCLC with untreated, symptomatic or recently-irradiated BM.

Methods: This multicenter, single-arm, phase 2 trial enrolled patients with treatment-naïve, brain-metastasized NSCLC. BM could be untreated or irradiated. Symptomatic or recently-irradiated BMs that were deemed clinically stable were allowed. Patients received tislelizumab (200 mg) plus pemetrexed (500 mg/m) and carboplatin (AUC =5) on day 1 every 3 weeks for 4 cycles, followed by maintenance with tislelizumab plus pemetrexed. Primary endpoint was 1-year progression-free survival (PFS) rate. Secondary endpoints included intracranial efficacy and tolerability. PD-L1 expression, tumor mutational burden (TMB) and genomic alterations were evaluated as potential biomarkers.

Results: A total of 36 patients were enrolled, 19.2% had prior brain radiotherapy, 8.3% had symptomatic BMs that required corticosteroids ≤10 mg/d or antiepileptics. Confirmed systemic and intracranial ORR (iORR) was 43.8% and 46.7%, respectively. One-year systematic PFS rate and One-year iPFS rate was 36.8% and 55.8%, respectively. About 41.7% patients had neurological adverse events, 90% patients had concordant intracranial-extracranial responses. No intracranial pseudoprogression or hyperprogression occurred. Patients with prior brain radiation trended towards higher systemic (83.3% . 34.6%) and iORR (75.0% . 42.3%). Similar intracranial efficacy was observed in tumors with different PD-L1 and TMB levels, while alterations in cytokine receptors pathway predicted higher iORR (P=0.081), prolonged systematic PFS [hazard ratio (HR) =0.16, P=0.021] and overall survival (OS) (HR =0.71, P=0.029).

Conclusions: Untreated or irradiated BMs in NSCLC follows a conventional response and progression pattern under immunochemotherapy with altered cytokine receptors pathway being a potential biomarker for systemic and intracranial outcomes.

References

Paz-Ares L, Ciuleanu T, Cobo M, Schenker M, Zurawski B, Menezes J . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):198-211. DOI: 10.1016/S1470-2045(20)30641-0. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Hou X, Zhou C, Wu G, Lin W, Xie Z, Zhang H . Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study. J Thorac Oncol. 2023; 18(6):769-779. DOI: 10.1016/j.jtho.2023.01.083. View

Goldberg S, Schalper K, Gettinger S, Mahajan A, Herbst R, Chiang A . Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020; 21(5):655-663. PMC: 7380514. DOI: 10.1016/S1470-2045(20)30111-X. View

Scoccianti S, Olmetto E, Pinzi V, Osti M, Di Franco R, Caini S . Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO. Neuro Oncol. 2021; 23(10):1750-1764. PMC: 8485442. DOI: 10.1093/neuonc/noab129. View

Tomczak K, Czerwinska P, Wiznerowicz M . The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015; 19(1A):A68-77. PMC: 4322527. DOI: 10.5114/wo.2014.47136. View

Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z . Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021; 7(5):709-717. PMC: 8017481. DOI: 10.1001/jamaoncol.2021.0366. View

Chen L, Douglass J, Kleinberg L, Ye X, Marciscano A, Forde P . Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018; 100(4):916-925. DOI: 10.1016/j.ijrobp.2017.11.041. View

Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B . Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. J Thorac Oncol. 2021; 16(12):2109-2120. DOI: 10.1016/j.jtho.2021.07.015. View

10.

Cagney D, Martin A, Catalano P, Redig A, Lin N, Lee E . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017; 19(11):1511-1521. PMC: 5737512. DOI: 10.1093/neuonc/nox077. View

11.

Chu X, Niu L, Xiao G, Peng H, Deng F, Liu Z . The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. Front Immunol. 2022; 13:875488. PMC: 9175180. DOI: 10.3389/fimmu.2022.875488. View

12.

Stein M, Pandey M, Xiu J, Tae H, Swensen J, Mittal S . Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases. JCO Precis Oncol. 2022; 3:1-13. DOI: 10.1200/PO.18.00376. View

13.

Peters S, Bexelius C, Munk V, Leighl N . The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016; 45:139-62. DOI: 10.1016/j.ctrv.2016.03.009. View

14.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

15.

Galldiks N, Kocher M, Ceccon G, Werner J, Brunn A, Deckert M . Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. Neuro Oncol. 2019; 22(1):17-30. PMC: 6954406. DOI: 10.1093/neuonc/noz147. View

16.

Marcus L, Fashoyin-Aje L, Donoghue M, Yuan M, Rodriguez L, Gallagher P . FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res. 2021; 27(17):4685-4689. PMC: 8416776. DOI: 10.1158/1078-0432.CCR-21-0327. View

17.

Enright T, Witt J, Burr A, Yadav P, Leal T, Baschnagel A . Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases. Clin Lung Cancer. 2020; 22(2):110-119. DOI: 10.1016/j.cllc.2020.10.014. View

18.

Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X . Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01). J Clin Oncol. 2022; 41(3):651-663. PMC: 9870236. DOI: 10.1200/JCO.22.00727. View

19.

Lin N, Lee E, Aoyama H, Barani I, Barboriak D, Baumert B . Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015; 16(6):e270-8. DOI: 10.1016/S1470-2045(15)70057-4. View

20.

Desai J, Deva S, Lee J, Lin C, Yen C, Chao Y . Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. J Immunother Cancer. 2020; 8(1). PMC: 7295442. DOI: 10.1136/jitc-2019-000453. View